When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
BioMonitor 2 Pilot Study: Early Experience With Implantation of the Biotronik BioMonitor 2 Implantable Cardiac Monitor.
BACKGROUND The BioMonitor 2 Pilot Study assessed the implantation procedure , the sensing amplitude and the remote monitoring transmission success rate of the second generation implantable cardiac monitor , the BioMonitor 2 ( Biotronik , Berlin , Germany ) . METHODS This was a prospect i ve , multi-centre , single-arm , non-r and omised study involving seven operators in five sites across Australia . Data were collected at implantation , during clinic visits at 1 week and 1 month post-implantation , and through wireless remote monitoring . RESULTS Thirty patients with indications for long-term cardiac monitoring underwent successful insertion of a study device . The median implantation time was 9 minutes ( interquartile range ( IQR ) 5 - 14 mins ) . The mean R-wave amplitude at 1 week was 0.75±0.39mV and remained stable over the follow-up period . Within 1 day , 97 % of the patients connected to the remote monitoring network and daily messages were transmitted on 93.8 % of all study days . Seventy-six per cent of patients transmitted at least one subcutaneous ECG ( sECG ) , with a median number of sECGs per patient of seven ( IQR 3 - 37 ) within 28 days . CONCLUSIONS The results of the BioMonitor 2 Pilot study confirm the excellent sensing amplitudes afforded by this new device and the utility of the implantation tools and technique . Patient compliance with and the transmission success rate of the home monitoring system were excellent
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .